UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease

Orphanet journal of rare diseases, 2020-09, Vol.15 (1), p.256-256, Article 256

2020

Volltextzugriff (PDF)

Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital

Blood coagulation & fibrinolysis, 2013-03, Vol.24 (2), p.194-198

2013

Volltextzugriff (PDF)

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2015-08, Vol.15 (8), p.464

2015

Volltextzugriff (PDF)

Analysis of genotype-phenotype correlation in Gaucher disease type 1 using machine learning techniques

Molecular genetics and metabolism, 2024-02, Vol.141 (2), p.107845, Article 107845

2024

Volltextzugriff (PDF)

Femur Infiltration: A Feature That Predict Bone Complications in Gaucher Disease. Re-Assessing Bone Marrow Involvement through Machine Learning

Blood, 2022-11, Vol.140 (Supplement 1), p.2605-2606

2022

Volltextzugriff (PDF)

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Blood, 2019-11, Vol.134 (Supplement_1), p.2323-2323

2019

Volltextzugriff (PDF)

Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic

Molecular genetics and metabolism, 2021-02, Vol.132 (2), p.S15-S15

2021

Volltextzugriff (PDF)

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Blood, 2020-11, Vol.136 (Supplement 1), p.13-14

2020

Volltextzugriff (PDF)

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Blood, 2021-11, Vol.138 (Supplement 1), p.2599-2599

2021

Volltextzugriff (PDF)

Impact of immunoparesis on Gaucher disease (GD): Results from a network relationship analysis of data at diagnosis of the patients included in the Spanish registry of GD

Molecular genetics and metabolism, 2020-02, Vol.129 (2), p.S21-S22

2020

Volltextzugriff (PDF)

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Blood, 2019-11, Vol.134 (Supplement_1), p.492-492

2019

Volltextzugriff (PDF)

Multiple myeloma and Gaucher disease share features of a cytokine profile

Molecular genetics and metabolism, 2015-02, Vol.114 (2), p.S13-S14

2015

Volltextzugriff (PDF)

Twenty-Five Years Diagnosing Gaucher's Disease in Spain, What We Have Learned?

Blood, 2018-11, Vol.132 (Supplement 1), p.1110-1110

2018

Volltextzugriff (PDF)

Follow-up of bone disease in a large cohort of Gaucher disease

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.S20-S20

2016

Volltextzugriff (PDF)

Assessing underlying chronic inflammation status in type 1 Gaucher disease patients (GD1): involvement of lipocaline (LCN2) and other monocyte cytokines

Molecular genetics and metabolism, 2017-01, Vol.120 (1-2), p.S22

2017

Volltextzugriff (PDF)

Twenty-five years diagnosing Gaucher disease in Spain: What we have learned?

Molecular genetics and metabolism, 2019-02, Vol.126 (2), p.S22-S22

2019

Volltextzugriff (PDF)

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

Blood, 2018-11, Vol.132 (Supplement 1), p.4942-4942

2018

Volltextzugriff (PDF)

TRAZELGA: Preliminary results of the Spanish prospective, multi-center follow-up study and immune activation markers in adult Gaucher disease patients treated with eliglustat

Molecular genetics and metabolism, 2020-02, Vol.129 (2), p.S21-S21

2020

Volltextzugriff (PDF)

Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project

Molecular genetics and metabolism, 2019-02, Vol.126 (2), p.S22-S23

2019

Volltextzugriff (PDF)

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2015-08, Vol.15 (8), p.464-471

2015

Volltextzugriff (PDF)

Gaucher disease type 3 in Spain. Outcomes and characterization

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.S20-S20

2016

Volltextzugriff (PDF)

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With90 Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2015, Vol.15 (8), p.464-471

2015

Volltextzugriff (PDF)

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

British journal of haematology, 2019-05, Vol.185 (3), p.480-491

2019

Volltextzugriff (PDF)

Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

British journal of haematology, 2021-03, Vol.192 (6), p.988-996

2021

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Hematology
(11)
Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Female
(8)
Male
(8)
Adult
(6)
Aged
(6)
Middle Aged
(6)
Adolescent
(3)
Aged, 80 And Over
(3)
Follicular Lymphoma
(3)
Immunotherapy
(3)
Lymphoma
(3)
Monoclonal Antibodies
(3)
Mutation
(3)
Prognosis
(3)
Rituximab
(3)
Targeted Cancer Therapy
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease

Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Analysis of genotype-phenotype correlation in Gaucher disease type 1 using machine learning techniques

Femur Infiltration: A Feature That Predict Bone Complications in Gaucher Disease. Re-Assessing Bone Marrow Involvement through Machine Learning

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Impact of immunoparesis on Gaucher disease (GD): Results from a network relationship analysis of data at diagnosis of the patients included in the Spanish registry of GD

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Multiple myeloma and Gaucher disease share features of a cytokine profile

Twenty-Five Years Diagnosing Gaucher's Disease in Spain, What We Have Learned?

Follow-up of bone disease in a large cohort of Gaucher disease

Assessing underlying chronic inflammation status in type 1 Gaucher disease patients (GD1): involvement of lipocaline (LCN2) and other monocyte cytokines

Twenty-five years diagnosing Gaucher disease in Spain: What we have learned?

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

TRAZELGA: Preliminary results of the Spanish prospective, multi-center follow-up study and immune activation markers in adult Gaucher disease patients treated with eliglustat

Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Gaucher disease type 3 in Spain. Outcomes and characterization

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With90 Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

Aktive Filter

Suchergebnisse filtern